High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Standard

High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. / Nielsen, Morten A; Salanti, Ali.

Malaria Vaccines : Methods and Protocols . Vol. 1325 Humana Press, 2015. p. 241-53 (Methods in molecular biology (Clifton, N.J.)).

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Harvard

Nielsen, MA & Salanti, A 2015, High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. in Malaria Vaccines : Methods and Protocols . vol. 1325, Humana Press, Methods in molecular biology (Clifton, N.J.), pp. 241-53. https://doi.org/10.1007/978-1-4939-2815-6_20

APA

Nielsen, M. A., & Salanti, A. (2015). High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. In Malaria Vaccines : Methods and Protocols (Vol. 1325, pp. 241-53). Humana Press. Methods in molecular biology (Clifton, N.J.) https://doi.org/10.1007/978-1-4939-2815-6_20

Vancouver

Nielsen MA, Salanti A. High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. In Malaria Vaccines : Methods and Protocols . Vol. 1325. Humana Press. 2015. p. 241-53. (Methods in molecular biology (Clifton, N.J.)). https://doi.org/10.1007/978-1-4939-2815-6_20

Author

Nielsen, Morten A ; Salanti, Ali. / High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. Malaria Vaccines : Methods and Protocols . Vol. 1325 Humana Press, 2015. pp. 241-53 (Methods in molecular biology (Clifton, N.J.)).

Bibtex

@inbook{376354b614694b1c9c4211826664e2f1,
title = "High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites",
abstract = "The particular virulence of Plasmodium falciparum manifests in diverse severe malaria syndromes as cerebral malaria, severe anemia and placental malaria. The cause of both the severity and the diversity of infection outcome, is the ability of the infected erythrocyte (IE) to bind a range of different human receptors through Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) on the surface of the infected cell. As the var genes encoding the large PfEMP1 antigens are extensively polymorphic, vaccine development strategies are focused on targeting the functional binding epitopes. This involves identification of recombinant fragments of PfEMP1s that induce antibodies, which hinder the adhesion of the IE to a given receptor or tissue. Different assays to measure the blocking of adhesion have been described in the literature, each with different advantages. This chapter describes a high-throughput assay used in the preclinical and clinical development of a VAR2CSA based vaccine against placental malaria.",
author = "Nielsen, {Morten A} and Ali Salanti",
year = "2015",
doi = "10.1007/978-1-4939-2815-6_20",
language = "English",
isbn = "978-1-4939-2814-9",
volume = "1325",
series = "Methods in molecular biology (Clifton, N.J.)",
publisher = "Humana Press",
pages = "241--53",
booktitle = "Malaria Vaccines",
address = "United States",

}

RIS

TY - CHAP

T1 - High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites

AU - Nielsen, Morten A

AU - Salanti, Ali

PY - 2015

Y1 - 2015

N2 - The particular virulence of Plasmodium falciparum manifests in diverse severe malaria syndromes as cerebral malaria, severe anemia and placental malaria. The cause of both the severity and the diversity of infection outcome, is the ability of the infected erythrocyte (IE) to bind a range of different human receptors through Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) on the surface of the infected cell. As the var genes encoding the large PfEMP1 antigens are extensively polymorphic, vaccine development strategies are focused on targeting the functional binding epitopes. This involves identification of recombinant fragments of PfEMP1s that induce antibodies, which hinder the adhesion of the IE to a given receptor or tissue. Different assays to measure the blocking of adhesion have been described in the literature, each with different advantages. This chapter describes a high-throughput assay used in the preclinical and clinical development of a VAR2CSA based vaccine against placental malaria.

AB - The particular virulence of Plasmodium falciparum manifests in diverse severe malaria syndromes as cerebral malaria, severe anemia and placental malaria. The cause of both the severity and the diversity of infection outcome, is the ability of the infected erythrocyte (IE) to bind a range of different human receptors through Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) on the surface of the infected cell. As the var genes encoding the large PfEMP1 antigens are extensively polymorphic, vaccine development strategies are focused on targeting the functional binding epitopes. This involves identification of recombinant fragments of PfEMP1s that induce antibodies, which hinder the adhesion of the IE to a given receptor or tissue. Different assays to measure the blocking of adhesion have been described in the literature, each with different advantages. This chapter describes a high-throughput assay used in the preclinical and clinical development of a VAR2CSA based vaccine against placental malaria.

U2 - 10.1007/978-1-4939-2815-6_20

DO - 10.1007/978-1-4939-2815-6_20

M3 - Book chapter

C2 - 26450394

SN - 978-1-4939-2814-9

VL - 1325

T3 - Methods in molecular biology (Clifton, N.J.)

SP - 241

EP - 253

BT - Malaria Vaccines

PB - Humana Press

ER -

ID: 162384416